Table 1.
Clinical data
| Clinical Characteristic | All Patients (N=474) | AL/AH/AHL (n=407) | AA (n=33) | ALECT2 (n=13) | AFib (n=6) | P Value (4 Way) |
|---|---|---|---|---|---|---|
| Age (yr) | 63 (11–89) | 64 (25–85) | 52 (11–83) | 68 (56–71) | 60 (47–67) | 0.004a |
| Sex (male/female) | 290/184 (61/39) | 243/164 (60/40) | 23/10 (70/30) | 9/4 (69/31) | 5/1 (83/17) | 0.50 |
| Serum creatinine | 1.3 (0.9–2.3) | 1.2 (0.9–2.1) | 2.4 (1.5–3.5) | 3.1 (2.1–3.6) | 4.1 (2.6–6.2) | <0.001b |
| Renal insufficiency | 240/461 (52) | 186/396 (47) | 26/32 (81) | 12 (92) | 4 (83) | <0.001c |
| Serum creatinine >2 mg/dl | 144/461 (31) | 103/396 (26) | 20/32 (63) | 10 (77) | 3/5 (67) | <0.001d |
| 24-h urine protein | 6 (3.4–10.0) | 6.2 (3.5–10.0) | 4.1 (2.9–11.5) | 4.1 (1.0–5.2) | 3.4 (2.9–4.2) | 0.02e |
| Serum albumin | 2.5 (1.9–3.1) | 2.4 (1.9–3.0) | 2.7 (1.7–3.0) | 3.4 (3.2–3.8) | 3.5 (3.2–3.7) | <0.001f |
| Peripheral edema | 345/441 (78) | 310/375 (83) | 17/25 (68) | 4/12 (33) | 5 (83) | 0.001g |
| Full nephrotic syndrome | 268/414 (65) | 244/360 (68) | 13/24 (54) | 2/12 (17) | 1 (17) | <0.001h |
Data are expressed as the median (interquartile range), ratio (%), or n (%). AL/AH/AHL, light chain/heavy chain/heavy and light chain amyloidosis; AA, AA amyloidosis; ALECT2, leukocyte chemotactic factor 2 amyloidosis; AFib, fibrinogen A α-chain amyloidosis.
Post hoc subtype analysis: AA versus others, P<0.001; AA versus AL/AH/AHL, P=0.004; AA versus ALECT2, P=0.001; AL/AH/AHL versus others, P=0.002.
Post hoc subtype analysis: AA versus AL/AH/AHL, P<0.001; AL/AH/AHL versus others, P<0.001; AL/AH/AHL versus ALECT2, P=0.001; AL/AH/AHL versus AFib, P=0.01.
Post hoc subtype analysis: AA versus AL/AH/AHL; P<0.001; AL/AH/AHL versus others, P<0.001; AL/AH/AHL versus ALECT2, P<0.001; AL/AH/AHL versus AFib, P=0.01; ALECT2/AFib versus AL/AH/AHL/AA, P=0.01.
Post hoc subtype analysis: AA versus AL/AH/AHL, P<0.001; AL/AH/AHL versus ALECT2, P<0.001; AL/AH/AHL versus AFib, P=0.05; AL/AH/AHL versus others, P<0.001; ALECT2 versus others, P<0.001; AFib versus others, P=0.07.
Post hoc subtype analysis: AL/AH/AHL versus others, P=0.01; ALECT2 versus others, P=0.03; AFib versus others, P=0.06.
Post hoc subtype analysis: AL/AH/AHL versus others, P=0.01; ALECT2 versus others, P=0.001; AFib versus others, P=0.003.
Post hoc subtype analysis: AL/AH/AHL versus others, P<0.001; ALECT2 versus others, P=0.001.
Post hoc subtype analysis: AL/AH/AHL versus others, P<0.001; ALECT2 versus others, P=0.001; AFib versus others, P=0.02.